Gossec L, Strand V, Proudfoot C, et al. - Two phase III, randomized, controlled trials of sarilumab in patients with active, longstanding RA were investigated in order to assess the impact of sarilumab on the patient-perceived influence of RA using the 7-domain RA Impact of Disease (RAID) scale. Sarilumab 150 mg and 200 mg + conventional synthetic disease-modifying antirheumatic drugs (csDMARD) were nominally better than placebo + csDMARD and 200 mg sarilumab vs adalimumab (ADA) 40 mg in least-squares mean variations for RAID total score at weeks 12 and 24 and all impacts of RA. In physical domains (eg, pain) compared with mental domains (eg, emotional well-being), impacts were greater. More individuals receiving sarilumab vs placebo or ADA listed betterments ≥ minimal clinically important difference and patient-acceptable symptom-state in total RAID scores at both evaluations. Hence, in comparison with placebo + csDMARD or ADA monotherapy, on the basis of the RAID, sarilumab + csDMARD or as monotherapy decreased the impact of RA on individuals’ lives to a greater degree.